Apple sues China's Oppo, ex-engineer over alleged theft of Watch secrets
Apple accused smartphone maker Oppo in a lawsuit of poaching a highly paid member of the Apple Watch team and encouraging him to steal trade secrets for his new job with the Chinese firm. Sensor system architect Chen Shi secretly accessed confidential documents on Apple's health-sensing ...
Apple Restores Blood-Oxygen Tracking To Watch After Customs Ruling - Masimo Strikes Back With Lawsuit Over Patent Rights - Masimo ( NASDAQ:MASI )
Apple Inc. AAPL has reintroduced the blood-oxygen monitoring feature to its Apple Watch lineup after U.S. Customs and Border Protection approved imports of the devices - a decision that medical technology firm Masimo Corp. MASI is now challenging in court.
Masimo Shares Dip Despite FDA Clears Expanded Use of O3 Monitoring
MASI gains FDA clearance to expand O3 monitoring with delta hemoglobin parameters across all patient groups.
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.
What's Going On With Apple Stock Thursday? - Masimo ( NASDAQ:MASI )
U.S. update restores Blood Oxygen to Apple Watch Series 9, Series 10, and Ultra 2. Masimo shares fall 3.4% as Apple reintroduces the disputed feature. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Masimo ( MASI )
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
Masimo ( MASI ) Beats Q2 Earnings and Revenue Estimates
Masimo (MASI) delivered earnings and revenue surprises of +8.13% and +0.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is the Market Bullish or Bearish on Masimo? - Masimo ( NASDAQ:MASI )
Masimo's MASI short percent of float has fallen 7.69% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 8.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their ...
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Masimo ( NASDAQ:MASI )
Masimo MASI has outperformed the market over the past 15 years by 1.64% on an annualized basis producing an average annual return of 14.03%. Currently, Masimo has a market capitalization of $8.92 billion.
Here's How Much You Would Have Made Owning Masimo Stock In The Last 10 Years - Masimo ( NASDAQ:MASI )
Masimo MASI has outperformed the market over the past 10 years by 4.06% on an annualized basis producing an average annual return of 15.46%. Currently, Masimo has a market capitalization of $8.81 billion.
Shareholder Alert: Johnson Fistel, LLP Investigates Elanco Animal Health, Masimo, Fidelity National Information, and Super Micro Computer -Long-Term Investors are Encouraged to Contact the Firm - Fidelity National Info ( NYSE:FIS ) , Elanco Animal Health ( NYSE:ELAN )
SAN DIEGO, July 03, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, a shareholder rights law firm, is investigating potential violations of federal and state laws by officers and directors of Elanco Animal Health Incorporated ELAN, Masimo Corporation MASI, Fidelity National Information ...
MASIMO CORPORATION INVESTIGATION ALERT: Johnson Fistel, PLLP Investigates Potential Breach of Fiduciary Duties by Masimo Officers and Directors - Masimo ( NASDAQ:MASI )
SAN DIEGO, June 27, 2025 ( GLOBE NEWSWIRE ) -- Leading shareholder rights law firm Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation MASI. The investigation centers on whether Masimo's ...
How Do Investors Really Feel About Masimo? - Masimo ( NASDAQ:MASI )
Masimo's MASI short percent of float has risen 3.19% since its last report. The company recently reported that it has 3.13 million shares sold short, which is 8.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.12 days to cover their ...
Apple Dodges $300 Million Patent Penalty As Appeals Court Cites Jury Instruction Errors In LTE Dispute With Optis - Apple ( NASDAQ:AAPL )
Apple Inc. AAPL avoided a $300 million patent infringement penalty on Monday after a federal appeals court ruled that faulty jury instructions violated the tech giant's constitutional rights in its dispute with patent licensing firm Optis Cellular Technology.
Here's How Much You Would Have Made Owning Masimo Stock In The Last 10 Years - Masimo ( NASDAQ:MASI )
Masimo MASI has outperformed the market over the past 10 years by 4.49% on an annualized basis producing an average annual return of 15.54%. Currently, Masimo has a market capitalization of $9.02 billion.
MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties - Masimo ( NASDAQ:MASI )
SAN DIEGO, June 10, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation MASI in relation to their obligations to the company's shareholders.
Here's How Much $100 Invested In Masimo 15 Years Ago Would Be Worth Today - Masimo ( NASDAQ:MASI )
Masimo MASI has outperformed the market over the past 15 years by 2.29% on an annualized basis producing an average annual return of 14.41%. Currently, Masimo has a market capitalization of $8.92 billion.
Is the Market Bullish or Bearish on Masimo? - Masimo ( NASDAQ:MASI )
Masimo's MASI short percent of float has risen 17.24% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 8.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their ...
MASI INVESTIGATION ALERT: Johnson Fistel PLLP Investigates the Directors and Officers of Masimo Corporation for Breach of Fiduciary Duties - Masimo ( NASDAQ:MASI )
SAN DIEGO, May 21, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, a shareholder rights law firm, announces it is investigating potential breaches of fiduciary duties by certain directors and officers of Masimo Corporation MASI in relation to their obligations to the company's shareholders.
Is Masimo ( MASI ) a Solid Growth Stock? 3 Reasons to Think "Yes"
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand
Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Masimo ( NASDAQ:MASI )
Masimo MASI has outperformed the market over the past 15 years by 1.69% on an annualized basis producing an average annual return of 12.79%. Currently, Masimo has a market capitalization of $8.01 billion.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Masimo ( MASI ) Q1 Earnings and Revenues Surpass Estimates
Masimo (MASI) delivered earnings and revenue surprises of 9.68% and 1.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
CNMD reports solid first-quarter results, driven by improving sales across both segments.
ALGN Q1 Earnings and Revenues Top Estimates, Stock Up in After-market
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
Is the Market Bullish or Bearish on Masimo? - Masimo ( NASDAQ:MASI )
Masimo's MASI short percent of float has fallen 3.59% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 7.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their ...
EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
